Gapping down
In reaction to disappointing earnings/guidance: NTSC -7.1%.
Other news: SCOK -23.0% (continued weakness; still checking for anything new), MTRX -3.3% (files an extension of time to file its 10-K for FY10 and Q4 earnings release due to recently discovered alleged fraudulent activities), PCX -2.8% (provides update for Q3: expected volume -10% from earlier est. to 7.5-7.7 mln tons ), VMW -1.9% (weakness attributed to negative mention in finance newspaper), SGEN -0.7% (phase IIb clinical trial of lintuzumab in older patients with acute myeloid leukemia did not meet its primary endpoint of extending overall survival; co will discontinue its development program for lintuzuma).
Analyst comments: AZO -1.3% (downgraded to Sell from Neutral at Goldman).
Gapping up
M&A news: GTSI +33.2% (Eyak Technology announces cash offer of $7.00/Share for GTSI), ARST +25.2% (ArcSight confirms it will be acquired by HPQ for $43.50 per share, or an enterprise value of $1.5 bln), DTG +5.0% (Dollar Thrifty and Hertz agree to $50/share offer).
Select financial related names showing strength: ING +3.6%, IRE +3.4%, RF +3.0% (upgraded to Outperform from Market Perform at Bernstein ), CS +3.0%, DB +3.0% (approves takeover offer for Postbank ), HBC +2.8%, PUK +2.8%, LYG +2.8%, AEG +2.7%, HBAN +2.6% (upgraded to Outperform from Market Perform at Bernstein), BAC +2.5%, UBS +2.1%, STD +1.7%, BCS +1.3%, .
Select metals/mining stocks trading higher: RTP +2.7%, TCK +2.4%, MT +2.3%, BBL +2.3%, BHP +2.1%, FCX +2.0%, AKS +1.9%, SVM +1.8%, AA +1.7%, MTL +1.7%, GFI +1.4%.
Select oil/gas related names showing strength: LNG +12.4% (continued momentum), CRZO +3.7%, CEO +3.6%, APC +3.2% (announces successful Owo-1 Sidetrack), STO +2.5%, RIG +2.4%, LLEN +2.2%, WLT +2.1%, RDS.A +1.6%, PBR +1.6%, BEXP +1.1% (announced a $250 mln sr notes offering).
Select European drug names trading higher: AZN +1.9%, SNY +1.4%.
Other news: OXGN +81.5% (ZYBRESTAT improves overall survival in a Phase 2/3 Trial of patients with Anaplastic Thyroid Cancer), INO +17.1% (achieves unprecedented T-Cell immune responses in human trial of DNA Vaccine for Cervical Dysplasia and Cancer caused by HPV ), ASTI +12.4% (signs distribution agreement with Radiant Holding, of China), XRX +5.4% (strength attributed to positive mention in finance newspaper), CGNX +4.7% (Cramer makes positive comments on MadMoney), VICL +4.2% (TransVax CMV Vaccine achieves statistical significance on key clinical endpoints in Phase 2 Trial), WSM +1.9% (ticking higher; authorizes a new $65 mln stock repurchase program), .
Analyst comments: MSFT +1.5% (initiated with a Buy at Standpoint Research), PXP +0.9% (upgraded to Buy from Hold at Hapoalim).